Cerebral Cavernous Malformation: From Genetics to Pharmacotherapy.

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Cerebral cavernous malformation (CCM) is a central nervous system cerebrovascular abnormality.
• CCM is associated with germline and somatic genetic mutations.
• Current understanding of CCM mechanisms is incomplete, with no definitive cure or preventative treatments.

Purpose of the Study:

• To review genetic mutations and molecular mechanisms of CCM.
• To explore current and potential pharmacological interventions for CCM.

Main Methods:

• Literature search conducted in PubMed and Web of Science.
• Focused on genetic mechanisms and pharmacological treatments of CCM.

Main Results:

• Germline and somatic mutations drive CCM development via molecular pathways.
• Drugs including statins, fasudil, rapamycin, and propranolol show potential in managing CCM symptoms and progression.
• These medications target specific pathways involved in CCM.

Conclusions:

• Understanding CCM molecular mechanisms is key to developing targeted therapies.
• Further investigation into novel mutations and treatment strategies is necessary.
• Improved patient outcomes depend on continued research in CCM.